Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG raised its earnings forecast for the third time this year as new drugs including gene therapy Zolgensma got off to a strong start. The Swiss drugmaker also lifted.

Novartis Boosts Forecast Again As New Gene Therapy Shines

Novartis earnings and sales topped Q3 views, with the Swiss drug giant also raising some full-year guidance. Novartis stock fell slightly early Tuesday.

Novartis Earnings Top; Swiss Drug Giant Edges Lower

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

Novartis announced positive results in its phase 3 study using Kisqali along with endocrine therapy to treat women with postmenopausal advanced breast cancer.

Novartis Delivers In Breast Cancer Study, Could Lead To A Major Battle With Competitors

Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.

Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval

Will recent developments at Novartis (NVS) make the stock more appealing to hedge funds?

New Novartis Drug Tabbed as Blockbuster

Novartis gained Food and Drug Administration approval Tuesday for an eye-disease treatment called Beovu that could undercut Regeneron Pharmaceuticals' blockbuster medicine, Eylea.
The post How Novartis Is Aiming To Undercut Regeneron's Biggest Moneymaker appeared first on Investor's Business Daily.

How Novartis Is Aiming To Undercut Regeneron's Biggest Moneymaker

Is  (NVS) Outperforming Other Medical Stocks This Year?

Is Novartis (NVS) Outperforming Other Medical Stocks This Year?

Bausch Health Companies Inc

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.

Novartis Reports Additional Data on Spondylitis Drug Cosentyx

Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.

Novartis (NVS) Announces Data on Asthma Drugs & Kisqali

Microsoft

Microsoft has reached a deal with pharmaceutical giant Novartis that aims to bring the power of artificial intelligence to drug discovery.

Microsoft will use AI to supercharge Novartis’ giant drug-development engine

Bausch Health Cos. Inc. BHC, +0.69% said Tuesday it is filing a lawsuit against Novartis AG unit Sandoz NVS, -0.57% for the infringement of patents protecting its Xifaxan 550 mg tablets, a treatment for irritable bowel syndrome.

Bausch files suit against Novartis unit Sandoz for infringing patents on Xifaxan 550 mg tablets

Biogen

Biogen is initiating a new Phase III trial for Spinraza in adult-onset SMA.

New Biogen Spinraza Trial Has Little To Do With Novartis Competition

Novartis achieved positive results for its phase 3 study using Cosentyx to treat patients with active non-radiographic axial spondyloarthritis.

Novartis Continues To Make Significant Strides Toward Boosting Sales Of Cosentyx

Novartis AG  blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so.

Novartis blames former AveXis executives for Zolgensma data manipulation

Novartis AG  laid the blame for the manipulation of data behind its $2.1 million gene therapy Zolgensma at the feet of the former executives Brian and Allan Kaspar, who it alleges either personally manipulated the data or pressured subordinates to manipulate the data.

Novartis blames former Avexis executives for Zolgensma manipulation

Novartis AG's  Sandoz unit said on Wednesday it was halting distribution of its versions of the drug commonly known as Zantac in all its markets, including the United States and Canada, after contaminants were found in the heartburn drug.

Novartis halts distribution of its Zantac versions amid probe into impurities

Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.

Novartis Announces New Data on Spondylitis Drug Cosentyx

Eli Lilly

Pfizer

The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.

Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert

Novartis received Breakthrough Therapy Designation for capmatinib for the treatment of metastatic MET exon 14 skipping mutated NSCLC.

Novartis Presses Forward With Plan To Get New Treatment Options For Subset Of NSCLC Population

Novartis ran two head-to-head studies, known as ASCLEPIOS I and ASCLEPIOS 2 respectively, where ofatumumab obtained superiority over Aubagio when it came to the primary endpoint of ARR.

Novartis Wants A Piece Of MS Market; Latest Data In Head-To-Head Studies Might Be The Key

Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.

Novartis Announces Positive Long-Term Data on Migraine Drug

Novartis  Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity.

News for Novartis Stock (NVS)